Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert F Storey

Showing results (371-380 of 401) with videos related to

Pageof 41
Sort By:
Journal of the American College of Cardiology|November 30, 2019
Timing of Staged Nonculprit Artery Revascularization in Patients With ST-Segment Elevation Myocardial Infarction: COMPLETE TrialDavid A Wood, John A Cairns, Jia Wang, et al.
Journal of the American Heart Association|December 21, 2018
Reduction in Subtypes and Sizes of Myocardial Infarction With Ticagrelor in PEGASUS-TIMI 54Marc P Bonaca, Stephen D Wiviott, David A Morrow, et al.
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions|October 25, 2018
Morphine and Ticagrelor Interaction in Primary Percutaneous Coronary Intervention in ST-Segment Elevation Myocardial Infarction: ATLANTIC-MorphineFrédéric Lapostolle, Arnoud W Van't Hof, Christian W Hamm, et al.
Angiology|February 18, 2025
Sub-optimal Internal Mammary Grafts: Incidence, Timing, and EtiologyEron Yones, Ann Cheng, Arfah Hazel Preston, et al.
Clinical Research in Cardiology : Official Journal of the German Cardiac Society|January 12, 2020
Impact of renal function on clinical outcomes after PCI in ACS and stable CAD patients treated with ticagrelor: a prespecified analysis of the GLOBAL LEADERS randomized clinical trialMariusz Tomaniak, Ply Chichareon, Dominika Klimczak-Tomaniak, et al.
Nature Reviews. Cardiology|June 13, 2022
P2Y<sub>12</sub> inhibitor monotherapy in patients undergoing percutaneous coronary interventionDavide Capodanno, Usman Baber, Deepak L Bhatt, et al.
European Heart Journal|August 27, 2014
Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary or valve interventions: a joint consensus document of the European Society of Cardiology Working Group on Thrombosis, European Heart Rhythm Association (EHRA), European Association of Percutaneous Cardiovascular Interventions (EAPCI) and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS) and Asia-Pacific Heart Rhythm Society (APHRS)Gregory Y H Lip, Stephan Windecker, Kurt Huber, et al.
Journal of the American College of Cardiology|November 12, 2013
Vorapaxar in acute coronary syndrome patients undergoing coronary artery bypass graft surgery: subgroup analysis from the TRACER trial (Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome)David J Whellan, Pierluigi Tricoci, Edmond Chen, et al.
JACC. Cardiovascular Interventions|June 17, 2019
Updated Expert Consensus Statement on Platelet Function and Genetic Testing for Guiding P2Y<sub>12</sub> Receptor Inhibitor Treatment in Percutaneous Coronary InterventionDirk Sibbing, Daniel Aradi, Dimitrios Alexopoulos, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|December 27, 2019
Impact of chronic obstructive pulmonary disease and dyspnoea on clinical outcomes in ticagrelor treated patients undergoing percutaneous coronary intervention in the randomized GLOBAL LEADERS trialMariusz Tomaniak, Ply Chichareon, Kuniaki Takahashi, et al.
Pageof 41

Showing results (371-380 of 401) with videos related to

Sort By:
Pageof 41
Journal of the American College of Cardiology|November 30, 2019
Timing of Staged Nonculprit Artery Revascularization in Patients With ST-Segment Elevation Myocardial Infarction: COMPLETE TrialDavid A Wood, John A Cairns, Jia Wang, et al.
Journal of the American Heart Association|December 21, 2018
Reduction in Subtypes and Sizes of Myocardial Infarction With Ticagrelor in PEGASUS-TIMI 54Marc P Bonaca, Stephen D Wiviott, David A Morrow, et al.
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions|October 25, 2018
Morphine and Ticagrelor Interaction in Primary Percutaneous Coronary Intervention in ST-Segment Elevation Myocardial Infarction: ATLANTIC-MorphineFrédéric Lapostolle, Arnoud W Van't Hof, Christian W Hamm, et al.
Angiology|February 18, 2025
Sub-optimal Internal Mammary Grafts: Incidence, Timing, and EtiologyEron Yones, Ann Cheng, Arfah Hazel Preston, et al.
Clinical Research in Cardiology : Official Journal of the German Cardiac Society|January 12, 2020
Impact of renal function on clinical outcomes after PCI in ACS and stable CAD patients treated with ticagrelor: a prespecified analysis of the GLOBAL LEADERS randomized clinical trialMariusz Tomaniak, Ply Chichareon, Dominika Klimczak-Tomaniak, et al.
Nature Reviews. Cardiology|June 13, 2022
P2Y<sub>12</sub> inhibitor monotherapy in patients undergoing percutaneous coronary interventionDavide Capodanno, Usman Baber, Deepak L Bhatt, et al.
European Heart Journal|August 27, 2014
Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary or valve interventions: a joint consensus document of the European Society of Cardiology Working Group on Thrombosis, European Heart Rhythm Association (EHRA), European Association of Percutaneous Cardiovascular Interventions (EAPCI) and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS) and Asia-Pacific Heart Rhythm Society (APHRS)Gregory Y H Lip, Stephan Windecker, Kurt Huber, et al.
Journal of the American College of Cardiology|November 12, 2013
Vorapaxar in acute coronary syndrome patients undergoing coronary artery bypass graft surgery: subgroup analysis from the TRACER trial (Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome)David J Whellan, Pierluigi Tricoci, Edmond Chen, et al.
JACC. Cardiovascular Interventions|June 17, 2019
Updated Expert Consensus Statement on Platelet Function and Genetic Testing for Guiding P2Y<sub>12</sub> Receptor Inhibitor Treatment in Percutaneous Coronary InterventionDirk Sibbing, Daniel Aradi, Dimitrios Alexopoulos, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|December 27, 2019
Impact of chronic obstructive pulmonary disease and dyspnoea on clinical outcomes in ticagrelor treated patients undergoing percutaneous coronary intervention in the randomized GLOBAL LEADERS trialMariusz Tomaniak, Ply Chichareon, Kuniaki Takahashi, et al.
Pageof 41